Metabolic and molecular imaging in neuro-oncology

Herholz, Karl; Coope, David; Jackson, Alan

doi:10.1016/s1474-4422(07)70192-8

Cited by 94 publications

(55 citation statements)

References 131 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar to our result, a previous autoradiography study (25) documented lower intratumoral binding in LGGs than GBM but, unlike our imaging study, did not examine PK11195 binding in normal tissue of the same patients with LGA. We even observed negative numeric values in LGGs, suggesting that the cerebellum as the reference region had higher residual TSPO binding than the LGGs.…”

Section: Discussionsupporting

confidence: 90%

The 18-kDa Mitochondrial Translocator Protein in Human Gliomas: An ¹¹C-(R)PK11195 PET Imaging and Neuropathology Study

Su¹,

Roncaroli²,

Durrenberger³

et al. 2015

J Nucl Med

Self Cite

View full text Add to dashboard Cite

The 18-kDa mitochondrial translocator protein (TSPO) is upregulated in high-grade astrocytomas and can be imaged by PET using the selective radiotracer 11 C-(R)PK11195. We investigated 11 C-(R)PK11195 binding in human gliomas and its relationship with TSPO expression in tumor tissue and glioma-associated microglia/macrophages (GAMs) within the tumors. Methods: Twenty-two glioma patients underwent dynamic 11 C-(R)PK11195 PET scans and perfusion MR imaging acquisition. Parametric maps of 11 C-(R)PK11195 binding potential (BP ND ) were generated. Coregistered MR/PET images were used to guide tumor biopsy. The tumor tissue was quantitatively assessed for TSPO expression and infiltration of GAMs using immunohistochemistry and double immunofluorescence. The imaging and histopathologic parameters were compared among different histotypes and grades and correlated with each other. Results: BP ND of 11 C-(R)PK11195 in high-grade gliomas was significantly higher than in low-grade astrocytomas and low-grade oligodendrogliomas. TSPO in gliomas was expressed predominantly by neoplastic cells, and its expression correlated positively with BP ND in the tumors. GAMs only partially contributed to the overall TSPO expression within the tumors, and TSPO expression in GAMs did not correlate with tumor BP ND . Conclusion: PET with 11 C-(R)PK11195 in human gliomas predominantly reflects TSPO expression in tumor cells. It therefore has the potential to effectively stratify patients who are suitable for TSPO-targeted treatment.

show abstract

Section: Discussionsupporting

confidence: 90%

The 18-kDa Mitochondrial Translocator Protein in Human Gliomas: An ¹¹C-(R)PK11195 PET Imaging and Neuropathology Study

Su¹,

Roncaroli²,

Durrenberger³

et al. 2015

J Nucl Med

Self Cite

View full text Add to dashboard Cite

show abstract

“…Integrated PET/MR opens new perspectives in biomedical research and clinical multimodality imaging [3][4][5][6]. In addition to better soft tissue contrast and lack of ionizing radiation exposure, MRI offers a wide range of advanced imaging techniques [7,8], such as apparent diffusion coefficient maps for quantification of cellular density [9], arterial spin labelling for measurement of blood flow [10], dynamic contrast enhancement to assess the characteristics of tumour vasculature, including perfusion, blood vessel permeability, blood volume and extravascular extracellular volume fraction [11], and quantification of tissue metabolite concentrations by calibrated 1 H-MR spectroscopy [12,13] or based on hyperpolarized 13 C [14].…”

Section: Introductionmentioning

confidence: 99%

Discrimination and anatomical mapping of PET-positive lesions: comparison of CT attenuation-corrected PET images with coregistered MR and CT images in the abdomen

Kuhn

Crook

Mader

et al. 2012

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose PET/MR has the potential to become a powerful tool in clinical oncological imaging. The purpose of this prospective study was to evaluate the performance of a single T1-weighted (T1w) fat-suppressed unenhanced MR pulse sequence of the abdomen in comparison with unenhanced low-dose CT images to characterize PET-positive lesions. Methods A total of 100 oncological patients underwent sequential whole-body 18 F-FDG PET with CT-based attenuation correction (AC), 40 mAs low-dose CT and two-point Dixonbased T1w 3D MRI of the abdomen in a trimodality PET/CT-MR system. PET-positive lesions were assessed by CT and MRI with regard to their anatomical location, conspicuity and additional relevant information for characterization. Results From among 66 patients with at least one PETpositive lesion, 147 lesions were evaluated. No significant difference between MRI and CT was found regarding anatomical lesion localization. The MR pulse sequence used performed significantly better than CT regarding conspicuity of liver lesions (p<0.001, Wilcoxon signed ranks test), whereas no difference was noted for extrahepatic lesions. For overall lesion characterization, MRI was considered superior to CT in 40 % of lesions, equal to CT in 49 %, and inferior to CT in 11 %. Conclusion Fast Dixon-based T1w MRI outperformed lowdose CT in terms of conspicuity and characterization of PET-positive liver lesions and performed similarly in extrahepatic tumour manifestations. Hence, under the assumption that the technical issue of MR AC for whole-body PET examinations is solved, in abdominal PET/MR imaging the replacement of low-dose CT by a single Dixon-based MR pulse sequence for anatomical lesion correlation appears to be valid and robust.

show abstract

“…FDG accumulation reflects the rate of glucose utilization in a tissue, and mapping of FDG uptake within the body is altered in various inflammatory and neoplastic diseases [16]. Therefore, FDG-PET has assumed an increasingly important role in clinics and neurosciences by detecting the alteration of glucose utilization shown in various intracranial diseases [10,13,15,25,28]. Recently, FDG-PET has become available in veterinary medicine to obtain metabolic information of intracranial inflammation and tumor [8,17,19].…”

mentioning

confidence: 99%

FDG Uptake of Normal Canine Brain Assessed by High-Resolution Research Tomography-Positron Emission Tomography and 7 T-Magnetic Resonance Imaging

et al. 2012

View full text Add to dashboard Cite

ABSTRACT. The purpose of this study was to assess the normal distribution of 18 F-fluoro-2-deoxy-D-glucose (FDG) uptake of canine brain structures using a high-resolution research tomography-positron emission tomography (HRRT-PET) and 7 T-magnetic resonance imaging (MRI) fusion system. FDG-PET and T2-weighted MRI of the brain were performed on 4 healthy laboratory beagle dogs. On MRI, regions of interests (ROIs) were manually drawn over 51 intracranial structures, including nine gross structures and 42 detailed structures. Relative standard uptake value ratio (rSUV=SUV of ROI/SUV of whole brain) was calculated for each ROI. The HRRT-PET and 7 T-MRI fusion imaging system demonstrated significant differences in glucose metabolism among various intracranial structures. Among gross structures, the midbrain and the pons and medulla oblongata had the highest uptake (rSUV: 1.12 ± 0.03) and lowest uptake (rSUV: 0.90 ± 0.06) of FDG, respectively. When rSUVs were calculated on detailed regions, the caudal colliculus and the longitudinal fibers of pons had the highest (rSUV: 1.62 ± 0.05) and the lowest (rSUV: 0.63 ± 0.03) glucose metabolism, respectively. Because the high resolution of PET-MRI fusion images provided clearly identifiable metabolic activities of canine brain, the HRRT-PET and 7 T-MRI fusion imaging might be a good tool for evaluation of intracranial diseases in canines. KEY WORDS: 7 T-MRI, canine brain, FDG, HRRT-PET.

show abstract

Metabolic and molecular imaging in neuro-oncology

Cited by 94 publications

References 131 publications

The 18-kDa Mitochondrial Translocator Protein in Human Gliomas: An ¹¹C-(R)PK11195 PET Imaging and Neuropathology Study

The 18-kDa Mitochondrial Translocator Protein in Human Gliomas: An ¹¹C-(R)PK11195 PET Imaging and Neuropathology Study

Discrimination and anatomical mapping of PET-positive lesions: comparison of CT attenuation-corrected PET images with coregistered MR and CT images in the abdomen

FDG Uptake of Normal Canine Brain Assessed by High-Resolution Research Tomography-Positron Emission Tomography and 7 T-Magnetic Resonance Imaging

Contact Info

Product

Resources

About

Metabolic and molecular imaging in neuro-oncology

Cited by 94 publications

References 131 publications

The 18-kDa Mitochondrial Translocator Protein in Human Gliomas: An 11C-(R)PK11195 PET Imaging and Neuropathology Study

The 18-kDa Mitochondrial Translocator Protein in Human Gliomas: An 11C-(R)PK11195 PET Imaging and Neuropathology Study

Discrimination and anatomical mapping of PET-positive lesions: comparison of CT attenuation-corrected PET images with coregistered MR and CT images in the abdomen

FDG Uptake of Normal Canine Brain Assessed by High-Resolution Research Tomography-Positron Emission Tomography and 7 T-Magnetic Resonance Imaging

Contact Info

Product

Resources

About

The 18-kDa Mitochondrial Translocator Protein in Human Gliomas: An ¹¹C-(R)PK11195 PET Imaging and Neuropathology Study

The 18-kDa Mitochondrial Translocator Protein in Human Gliomas: An ¹¹C-(R)PK11195 PET Imaging and Neuropathology Study